News

Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

2 months ago

Jones Healthcare Group’s Qube Pro Wins Prestigious PAC Global Awards

Innovation and Sustainability Lead to Double Award Win for Qube Pro at PAC GlobalLondon, Ontario--(Newsfile Corp. - February 8, 2024)…

2 months ago

Planet 13 Announces Expansion of Leadership Team and Board

LAS VEGAS, NV / ACCESSWIRE / February 8, 2024 / Planet 13 Holdings Inc. (CSE:PLTH)(OTCQX:PLNH) ("Planet 13" or the "Company"),…

2 months ago

Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences

ANN ARBOR, MI / ACCESSWIRE / February 8, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…

2 months ago

Sai Life Sciences releases its Sustainability Report 2023

Sustainability Report 2023 Sustainability Report 2023 HYDERABAD, India, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sai Life Sciences, a leading global…

2 months ago

A clearer vision for surgical robotics: CMR Surgical announces significant update to Versius

A clearer vision for surgical robotics: CMR Surgical announces significant update to Versius CMR Surgical launches vLimeLite * a new…

2 months ago

SweetWater Brewing and Atlanta Track Club Join Forces to Promote Active Lifestyles

SweetWater Brewing is now the Official Beer Partner of the Atlanta Track Club SweetWater Brewing Company x Atlanta Track Club…

2 months ago

Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™

- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease -PRINCETON, N.J., Feb. 08,…

2 months ago

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and…

2 months ago